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This study was to determine the effects of allogenic
umbilical cord blood (UCB)-derived mesenchymal stem
cells (MSCs) and recombinant methionyl human
granulocyte colony-stimulating factor (rmhGCSF) on a
canine spinal cord injury model after balloon compression
at the first lumbar vertebra. Twenty-five adult mongrel
dogs were assigned to five groups according to treatment
after a spinal cord injury: no treatment (CN); saline
treatment (CP); rmhGCSF treatment (G); UCB-MSCs
treatment (UCB-MSC); co-treatment (UCBG). The UCB-
MSCs isolated from cord blood of canine fetuses were
prepared as 10
6 cells/150 µl saline. The UCB-MSCs were
directly injected into the injured site of the spinal cord and
rmhGCSF was administered subcutaneously 1 week after
the induction of spinal cord injury. The Olby score,
magnetic resonance imaging, somatosensory evoked
potentials and histopathological examinations were used to
evaluate the functional recovery after transplantation. The
Olby scores of all groups were zero at the 0-week evaluation.
At 2 week after the transplantation, the Olby scores in the
groups with the UCB-MSC and UCBG were significantly
higher than in the CN and CP groups. However, there were
no significant differences between the UCB-MSC and
UCBG groups, and between the CN and CP groups. These
comparisons remained stable at 4 and 8 week after
transplantation. There was significant improvement in the
nerve conduction velocity based on the somatosensory evoked
potentials. In addition, a distinct structural consistency of
the nerve cell bodies was noted in the lesion of the spinal
cord of the UCB-MSC and UCBG groups. These results
suggest that transplantation of the UCB-MSCs resulted in
recovery of nerve function in dogs with a spinal cord injury
and may be considered as a therapeutic modality for spinal
cord injury.
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Introduction
Regeneration of the central nervous system is limited after
injuries related to ischemia, trauma and degenerative disease
[33]. Recently, cell transplantation therapy has been considered
for treatment in the field of regenerative medicine [3,27]. At
the early stages of these studies, neural stem cells were
obtained mainly from fetal tissue to explore their use for
regeneration [5]. However, due to their limited availability
alternative sources of cells for neural transplantation, such as
embryonic, bone marrow, adipose and umbilical cord blood
(UCB) stem cells are being evaluated [27,30,41]. The cells
obtained from these additional sources can survive, proliferate,
migrate, and differentiate into neuronal phenotypes in the
damaged brain and spinal cord [1,21,34,40].
UCB stem cells, used for cell therapy, have advantages
over the use of other sources of stem cells [4]. UCB cells
have more mesenchymal progenitor cells per volume, and
are more pluripotent and genetically flexible than bone
marrow-derived mesenchymal stem cell [4,7]. In addition, it
has been suggested that they are not as mature as other adult
stem cells so that they may not elicit alloreactive responses
that modulate the immune system [2,13,16,37]. Furthermore,
they have been shown to have lower carcinogenic potential
than embryonic stem cells [15].
Recently, UCB stem cells have been shown to differentiate
into neural cells in vitro [7,8]. In addition, functional
recovery after transplantation of UCB stem cells into an
injured area of the spinal cord in vivo [40] and the efficacy
of intravenous administration of UCB stem cells in traumatic
brain injury have been demonstrated [20]. Furthermore,
there has been a report on recovery after transplantation of
UCB stem cells with neurotrophic factors [15]. The treatment
with granulocyte colony-stimulating factor (GCSF) has been
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shown to stimulate bone marrow stem cell proliferation and
mobilization [25].
Although canine bone marrow-derived mesenchymal
stem cells have been isolated and characterized in many
studies, there are only a few reports on the isolation of
mesenchymal stem cells from canine cord blood (UCB-
MSCs) [22,34]. In this study, using a previously developed
modified canine acute spinal cord injury model [19], we
examined the effectiveness of canine UCB-MSCs and
recombinant methionyl human GCSF (rmhGCSF) on the
improvement of neurological function.
Materials and Methods
Animals
Twenty-five healthy adult mongrel dogs that weighed
3.77 ± 0.59 kg, were used for the experimental spinal cord
injury study. This investigation was performed according to
the guidelines of the ‘Guide for the Care and Use of
Laboratory Animals’ of Seoul National University. The
dogs were assigned, without bias, to five groups according
to treatment after spinal cord injury. The control group with
no treatment (CN: n = 5); the control group with media-
injection (CP: n = 5); the group with subcutaneous injection
of rmhGCSF (G: n = 5); the group with transplantation of
canine UCB-MSCs into the spinal cord injury site (UCB-
MSC: n = 5); the groups with transplantation of canine
UCB-MSCs and subcutaneous injection of rmhGCSF
(UCBG: n = 5).
Induction of spinal cord injury
The spinal cord injury (SCI) was performed using balloon
compression methods as described previously [19]. Briefly,
the dogs were anesthetized with intravenous administration
of diazepam (Melode; Dong Wha Pharm, Korea) at a dose
of 0.3 mg/kg and propofol (Anepol; Ha Na Pharm, Korea) at
6 mg/kg with atropine sulfate (Atropine; Je Il Pharm, Korea)
at 0.05 mg/kg subcutaneously. Anesthesia was maintained
by inhalation of 2% isoflurane (Aerane; Ilisung, Korea).
Datex-Ohmeda (Microvtec Display, UK) was used for
monitoring of physiologic measures including rectal temperature,
oxygen saturation and pulse rate during anesthesia. The
dogs were placed in a ventral recumbent position. The
hemilaminectomy was performed by a left paramedian
approach at L4. A three to five millimeter hole was made in
the left vertebral arch at L4 using a high-speed pneumatic
burr. A three-French embolectomy catheter (SORIN Biomedica,
Italy) was inserted into the hole made at the L 4 vertebral
arch. The balloon was advanced, under fluoroscopic guidance,
until the tip of the catheter was placed at the cranial margin
of the L1 vertebral body. The balloon was then inflated 150
µl by injection of a contrast agent (Omnipaque; Amersham
Health, Ireland) diluted 50 : 50 with saline. The soft tissues
and skin were closed as per standard methods. The balloon
was fixed with a Chinese finger type suture, and then
removed after 12 h. After the operation, the dogs were
monitored in an intensive care unit, and if needed, manual
bladder expression was performed at least three times daily
until voluntary urination was established.
Preparations of canine UCB-MSCs
Cell collection: UCB was obtained during the Caesarian
section of a 58 kg mongrel dog at Seoul National University
Veterinary Medical Teaching Hospital. Eight ml of blood
was collected using 10 ml plastic syringes that contained 2
ml of citrate-phosphate-dextrose anticoagulant.
Isolation and culture of UCB-MSCs: The low-density
mononuclear cells were isolated using Ficoll-Plaque Plus
(Amersham Biosciences, Sweden). Then, the cells were
cultured in growth medium [Dulbeco’s Modified Eagle
media-low glucose with the addition of 10% fetal bovine
serum (Gibco-BRL, USA) with 2 mmol/l L-glutamine (Gibco-
BRL, USA)] and 0.3% penicillin-streptomycin (Gibco-
BRL, USA) at 37
oC and 5% CO2 concentration [26]. The
UCB-MSCs were cultured and the mononucleated cells that
proliferated from the cord blood were characterized by
FACS analysis [11]. The cells were prepared as 1 × 10
6 in
150 µl of saline solution for the injection.
Transplantation of canine UCB-MSCs and injection of
rmhGCSF: Transplantation of canine UCB-MSCs was
performed a week after the SCI. The dogs were anesthetized
using the same methods described above. The CN group did
not have any cells or medium transplanted after the injury. In
the CP group, a laminectomy was performed and the injured
site was exposed by a durotomy. One hundred and fifty
micro liters of saline was injected into the spinal cord at
three locations (center of the injury, 1.0 mm proximal and
1.0 mm distal to the injury, 3.0 mm in depth) using a 30
gauge needle. The incision region of the dura mater was
sutured with 8.0 absorbable materials. The remaining lesion
was closed routinely. In the UCB-MSCs group, 1 × 10
6 of
cells suspended in 150 µl of saline solution were injected at
the SCI site. In the UCBG group, 1 × 10
6 of cells suspended
in 150 µl of saline solution were injected at the SCI site and
100 µl of rmhGCSF solution (GCSF; Dong Wha Pharm,
Korea) was injected subcutaneously for 7 days, once a day.
The rmhGCSF was prepared with 5 µg/animal/day and
diluted with sterilized saline. In group G, 100 µl of rmhGCSF
solution was injected using the same method as in the
UCBG group.
Evaluations
Behavioral assessment: Behavioral assessment was
performed to evaluate the functional recovery of the hind
limbs. Each dog was videotaped for a minimum of 10 steps
from both sides and behind when walking on the floor. DogsFunctional recovery after transplantation of umbilical cord blood-derived stem cells 277
with non-weight bearing on their hind limbs were also
videotaped, supported by holding the base of their tail.
Using a 15-point scoring system (Olby score), the dogs’ gait
was independently scored from the videotapes by two
individuals unaware of the experimental conditions [24]. A
mean score at 0, 2, 4, and 8 weeks after the SCI was
calculated.
Somatosensory evoked potential assessment: Somato-
sensory evoked potentials (SEP) were measured using the
Neuropack 2 (Nihon Kohden, Japan) and two subdermal
channels at 0, 4 and 8 weeks after the cell transplantation.
Channel 1 was located in the subdermal region at the
midline between the sixth and seventh lumbar vertebra and
channel 2 was positioned between the tenth and eleventh
thoracic vertebra using platinum needle Grass stimulating
electrodes (Astro-Med, USA). The posterior tibial nerve
was stimulated for 0.2 msec, with 2 Hz and 3 mA [39]. The
latency response was converted into the velocity as a
measure of spinal cord dysfunction with the evoked
potentials. Spinal conduction velocity (CV) from L 6~L7 to
T10~T11 was calculated by the following equation [39]:
Conduction velocity (m/sec) = distance (cm) of two points/
latency (msec) difference × 10.
Magnetic resonance image: Magnetic resonance imaging
(MRI) was performed with a 0.2 Tesla Magnet scanner
(Esaote, Italy) at a week after the SCI and at 4 and 8 weeks
after the cell injection. The majority of the images obtained
were interleaved 5.0 mm with a slice thickness of 5.0 mm.
The repetition time (TR) and time to echo (TE) were
adjusted. T1-weighted (T1W) (TR/TE = 540/26 msec) and
T2-weighted (T2W) echo (TR/TE = 380/90 msec) images
were obtained. All dogs in each of the groups were examined
and the spinal cord injury lesions expressed in T2W sagittal
planes at 0, 4 and 8 weeks after the injury.
Histopathological assessment: To assess the histopathological
changes, all dogs were euthanized at 8 weeks after the cell
treatment. The spinal cords from T10 to L4 of all dogs were
sampled and fixed in 10% buffered neutral formalin. And then
the tissues were rountinely processed, embedded and
sectioned at 4 µm. These sections were mounted on silane-
coated slide glass. The slides were stained with hematoxylin
and eosin (H&E) to detect vacuolar formation and Luxol fast
blue to identify myelin [6]. The volumes of the cavities in
the damaged spinal cord were calculated from images of the
transverse sections using image analyzer software (ImageJ
version 1.37; National Institutes of Health, USA). The
myelinated area was analyzed using the same software.
These two analyses were performed at the epicenter of the
damaged spinal cord.
Statistical analysis: Data was expressed as the mean ±
SD. Statistical analysis was carried out using SPSS 12.0
software (SPSS, USA). The statistical significance of the
differences among group means was assessed using a one-
way ANOVA. A p < 0.05 was considered significant.
Results
Behavioral outcomes
The Olby scores for the degree of nerve function, in all
groups, was zero at 0 week. The Olby scores in the groups
UCB-MSC, G and UCBG were increased 1.2, 0.8 and 1.4 at
2 weeks after treatment and 7.4, 3.0 and 4.2 at 8 weeks,
respectively (Fig. 1). However, the increase in the Olby
scores in the CN and CP groups was below 1.0 until 8
weeks. The Olby scores in the UCB-MSC and UCBG
groups were significantly higher than in the CN and CP
groups from 2 weeks onward after treatment. However,
there were no significant differences between the UCB-
MSC and UCBG groups and between the CN and CP
groups. Group G did not show any significant difference
from the other groups at 2 weeks. However, group G had
significantly lower Olby scores than the UCB-MSC and
UCBG groups at 4 and 8 weeks, although there were no
differences between the UCB-MSC and UCBG groups at
this time.
Somatosensory evoked potentials
The somatosensory evoked potentials of the posterior
tibial nerves at the thoracic level revealed no response in all
groups at 0 week (Table 1). At 4 weeks, it was possible to
measure the evoked potentials in the G, UCB-MSC and
UCBG groups. However, the CP and CN showed no
responses until 8 weeks. The conduction velocities in G,
UCB-MSC and UCBG at 8 weeks were improved up to
43.92 ± 37.77 m/s, 48.92 ± 26.13 m/s and 39.64 ± 30.99 m/
s, respectively.
Fig. 1. Olby scores during 8 weeks. The groups of UCB-MSC
and UCBG improved more as shown with their functional scores
compared with the groups of CN and CP at 2 week after
transplantation (p < 0.05). The UCBG and UCB-MSC groups
were significantly improved as compared with all other groups a t
8 week after transplantation (p <0 . 0 5 ) .278 Ji-Hey Lim et al.
MRI results
Most dogs in all of the groups showed clear hyperintense
signals in the T2W sagittal plane at the L1 lesion at 1 week
after the SCI (Fig. 2). The CN and CP groups had a similar
appearance at the injured site that became a clearer
hyperintense area, in the parenchyma at the L 1 level, until 9
weeks after the SCI. The hyperintense area in the T2W
sagittal plane at the L1 level was decreased in two dogs in
the group G at 8 weeks. One of the dogs in the UCBG group
had a slightly decreased hyperintense lesion in the T2W
sagittal plane at the L1 level. In the UCB-MSC group, one
dog showed a normointense intramedullar lesion but it was
narrower than the near normal appearing areas.
Histopathological findings
At 8 weeks after treatment, the margins of normal grey
and white matter were not identified in all of the dogs
studied. There was a generalized infiltration of fibrous tissue
and adhesions in the dura mater. Most of the dogs in the CN
and CP groups showed damaged tissues and severe vacuolar
formation. Cavity formation and Luxol fast blue positive
area were very small in the CP group (Fig. 3A & B). The G
Table 1. Mean conduction velocities calculated from the
somatosensory evoked potentials at week 0, 4 and 8
Groups
Weeks
04 8
CN NE NE NE
CP NE NE NE
GN E *22.24 ± 9.70* 43.92 ± 37.77
UCB- MSC NE 26.54 ± 9.48 48.92 ± 26.13
UCBG NE 025.44 ± 16.98 39.64 ± 30.99
*m/sec, CN: no treatment, CP: saline treatment, G: rmhGCSF treatment,
UCB-MSC: umbilical cord blood-derived mesenchymal stem cell
treatment, UCBG: co-treatment, NE: no effects. All values are mean ± SD.
Fig. 2. Magnetic resonance images of the spinal cord in T2W sagittal view of the group CN (A & B), CP (C & D), G (E & F), UCB-
MSC (G & H) and UCBG (I & J). Most of the dogs were shown the clear localization of the spinal cord injury lesion (circle). A,  C, E, G
and I: Before cell transplantation, 1 week after spinal cord injury. B, D, F, H and J: 8 weeks after cell transplantation.Functional recovery after transplantation of umbilical cord blood-derived stem cells 279
group showed severe crushing damage in both the white and
grey matters as well as cavity formation (Fig. 3C & D).
Although the UCB-MSC group showed similar histological
findings with the other groups, neuronal cell like structures
in a small area were observed (Fig. 3E-G). The mean
percentage of cavities in the CN, CP, G, UCB-MSC and
UCBG groups were 41.06 ± 10.39, 2.64 ± 4.55, 21.37 ± 17.13,
6.55 ± 4.69, and 16.30 ± 11.46, respectively (p < 0.05)
(Table 2). The CN group showed a significantly higher
percentage of cavity formation. The mean percentages of
areas stained with Luxol fast blue in the CN, CP, G, UCB-
MSC, and UCBG groups were 13.70 ± 9.27, 8.39 ± 9.63,
30.39 ± 13.65, 46.33 ± 7.02, and 33.87 ± 25.33, respectively
(p < 0.05).
Discussion
The Olby scoring system was used for quantitative
evaluation of functional outcomes in this study. Olby et al.
modified the BBB open field scoring system for dogs based
on the pelvic limbs [24]. Several investigators have confirmed
the reliability of the Olby scoring system [23,38]. The spinal
cord injury model in the present study had more than 75% of
the spinal canal occluded during a 12 h period; the resulting
lesions showed histopathologically severe hemorrhage and
vacuolar formation. The dogs had paraplegia and were not
expected to regain a normal gait without treatment [6] as
demonstrated in the control groups, CN and CP, with or
without saline injection. In the CN and CP groups, the dogs
Fig. 3. Histopathological findings at 8 weeks after cell transplantation. (A) The epicenter of injured spinal cord of a dog in the gro up CP,
which showed small cavity formation with a little Luxol fast blue positive area. Luxol fast blue stain. Counterstain with cresy l violet.
×12.5. (B) High magnification of A. ×40. (C) The epicenter of injured spinal cord of a dog in the group G, which was crushed an d
damaged in both white and grey matters with cavity formation. H&E stain. ×12.5. (D) Same lesion as C. It showed small amount o f
remained myelin (arrow). Luxol fast blue stain. Counterstain with cresyl violet. ×12.5. (E) The epicenter of injured spinal cor d of a dog
in the group UCB-MSC, which revealed abnormal structures, however it showed structural consistency with nerve cell body (circle ).
H&E stain. ×12.5. (F) High magnification of E (circle). H&E stain. ×400. (G) Nerve cell body in the same lesion of F (arrows).  Luxol
fast blue stain. Counterstain with cresyl violet. ×400.
Table 2. Percentages of cavity formation and Luxol fast blue
staining positive area in transverse section of the epicenter of
injured spinal cord
Groups Cavity formation (%) Positive area (%)
CN 41.06 ± 10.39
a 13.70 ± 9.27
a0
CP 2.64 ± 4.55
b 8.39 ± 9.63
a
G
b21.37 ± 17.13
ab 30.39 ± 13.65
b
UCB-MSC 6.55 ± 4.69
b 46.33 ± 7.02
b0
UCBG
b16.30 ± 11.46
ab 33.87 ± 25.33
b
a,bSignificant differences (p < 0.05). All values are mean ± SD.280 Ji-Hey Lim et al.
had Olby scores below one until 9 weeks after the injury.
However, in the group with UCB-MSCs the Olby scores
increased from 2 weeks and were over 6 at 8 weeks; the
weight-bearing of the pelvic limbs improved from 10 to
50% of the time. Therefore, the group with UCB-MSCs
appeared to have improved spinal cord function after the
experimentally induced spinal cord injury.
A severe spinal cord injury results in the formation of glial
scar rimming, a cavitation that becomes a fluid-filled cyst
[33]. This fluid filled cyst may be bypassed by building new
connections with new neurons provided by the differentiation
of exogenous cells [35]. If guidance is provided, with a
bridge or scaffold made up of various cells or materials, for
connection to the distal and proximal ends of the spinal cord,
the injured cord may offer support for the transplanted cells
to facilitate regeneration [35,40]. Although we did not
confirm the fate of the transplanted stem cells, we found a
smaller percentage of cavity formation in the UCB-MSC
and UCBG groups. In addition, the CP group demonstrated
the smallest percentage of cavity formation; however, a few
myelinated areas remained compared with the UCB-MSC
and UCBG groups. Our histopathology data suggested that
transplantation of the UCB-MSCs might improve the
functional outcome of spinal cord injury by creating new
neuronal pathways in the fibrous scar tissues.
In the present study, the UCB-MSC group showed
significantly higher Olby scores than the G group from 4
weeks after cell transplantation. There was no difference
between the UCB-MSC and UCBG groups and between the
UCBG and G groups. Our results suggest that GCSF had no
beneficial effect on the spinal cord injury. However, it was
reported that GCSF could stimulate bone marrow stem cells
to proliferate and mobilize [25]. The GCSF stimulates
neurogenesis via the vascular endothelial growth factor [12].
The GCSF enhances angiogenesis by increases of endothelial
proliferation, vascular surface area and vascular branch
points after focal CNS ischemia [18]. The angiogenic effects
of GCSF reduce the function of the blood brain barrier after
central nervous system disruption [14,25]. It has been shown
that GCSF, under certain circumstances, such as when
combined with multiple doses of cytotoxic agents, may have
adverse effects on stem cells including direct damage to
stem cells [36]. The UCBG group was not exposed to any
cytotoxic agents in this study. We administered the GCSF by
a different route for 7 days, which might have affected the
UCB-MSCs. There is the possibility of a down regulation of
the proliferation of the UCB-MSCs related with the
administration of GCSF.
Percutaneous recording of electrical activity, in the spinal
cord, is an accurate method for spinal cord function assessment
[28]. The conduction velocities calculated from SEP
amplitudes and latencies revealed the cord damage severity
in the experimentally induced SCI [29]. Generally, the SEP
has a flat waveform when the spinal cord is injured by more
than fifty percent [17]. In this study, the neurological status
of the CN and CP groups was consistent with a flat
waveform until 8 weeks. However, the values of the SEP
recordings were similar even though a different clinical
status was shown in the G, UCB-MSC and UCBG groups.
Their measurement revealed that a minimal connection was
responsible for the values in the recording. However, these
values did not discriminate the various clinical grades
observed.
When the MR images were compared to the pathology
specimens, the spindle-shape of the high intensity area in the
spinal cord on the T2W images corresponded to the fibrous
area, and the low intensity areas reflected cavity formation
in the chronic phase [6]. In the present study, there were
markedly hyper- or hypo-intense areas in the CN and CP
groups after 8 weeks. However, all of the lesions in the
UCB-MSC and UCBG groups had a decrease of the hyper-
intense areas after 8 weeks. Similar findings have been
reported in severe human spinal cord injuries [13].
Neural stem cells isolated from embryonic and adult brain
tissues, and both mouse and human umbilical cord blood
derived multipotent stem cells, have been used for repair of
central nervous system injury [27,40,41]. Adipose-derived
stem cells have been reported to have a therapeutic potential
for neurological disorders [31]. It is unclear what the
mechanism is by which allogenic UCB-MSCs transplantation
induces recovery of spinal cord function. In a rat model, it
was reported that the stem cells expressed glial fibriliary
acidic protein or neuronal nuclear antigens [40]. The stem
cells have the characteristic of specific homing and the
expression of inflammatory molecules including adhesive
molecules, chemokines, cytokines, and chemokine receptors
at the injured site [4]. Tracking studies of MSCs, in vivo,
with MRI or immunohistochemistry have demonstrated the
fate of cells; these cells have been observed to integrate into
the areas with lesions in the central nervous system [10,32].
In addition, endogeneous neural progenitor cells may be
activated by injury and rapidly divide to replace damaged
cells [9].
Although the results of this study showed that there was
evidence of functional and sensory improvement after allogenic
UCB-MSCs transplantation, there was no evidence of
regeneration of spinal cord tissue by magnetic resonance
imaging and histology. However, there was no additional
damage to the experimentally injured spinal cord such as
inflammatory responses after direct transplantation into the
cord with allogenic UCB-MSCs. In addition, we observed
new neuronal formation in the injured structures of the
spinal cord in the UCB-MSC and UCBG groups. Therefore,
the results of this study showed that transplantation of UCB-
MSCs resulted in recovered nerve function in dogs after a
spinal cord injury. Such transplantation procedures may
provide a good therapeutic option for recovery after spinal
cord injuries. Further investigation on the fate of UCB-Functional recovery after transplantation of umbilical cord blood-derived stem cells 281
MSCs after transplantation is needed to confirm the role of
stem cells in the regeneration of the spinal cord after an
injury.
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